The popularity of copyright’s blockbuster initially fueled a surge for pharma, but recent shifts present a murky picture for investors. Lower-cost competitors are reducing earnings, and persistent legal battles add further complexity to the equation. While some companies could still see gains from adjacent products, the general trend suggests a … Read More